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Elevated blood pressure (BP) is a worldwide burden, leading to over 10 million deaths yearly. May Measurement Month
(MMM) is a global initiative organized by the International Society of Hypertension aimed at raising awareness of hypertension
and the need for BP screening. An opportunistic cross-sectional survey of volunteers aged 18 was carried out in May 2017.
BP measurement, the definition of hypertension and statistical analysis followed the globally approved MMM17 Study
Protocol. In Poland 5834 (98.9%, Caucasian) individuals were screened. After multiple imputation, 2601 (35.3%) had hyper-
tension. Of individuals not receiving anti-hypertensive medication, 976 (20.6%) were hypertensive. Of individuals receiving
anti-hypertensive medication, 532 (49.1%) had uncontrolled BP. In the crude screened group, 81.4% declared to not receive
any anti-hypertensive treatment, while the remaining 18.6% were on such medications. In overweight and obese patients
both systolic and diastolic BP were significantly higher than in normal weight and underweight subjects. In addition, BP mea-
sured on Sundays was significantly lower than on Mondays. MMM17 was one of the largest recent BP screening campaigns in
Poland. We found that over 1/3 of participants were hypertensive. Almost half of the treated subjects had uncontrolled BP.
These results suggest that opportunistic screening can identify substantial numbers with raised BP.
Background
Hypertension is considered the major modifiable, risk fac-
tor for all cardiovascular diseases (CVDs), all over the world
and the leading global cause of CVD mortality. In 2011, in
Poland the NATPOL 2011 Survey was performed to assess
the prevalence and control of CV factors, including hyper-
tension in 2401 subjects.1 Hypertension was detected in
33%. One of the largest Polish epidemiological study
WOBASZ (Multi-centre National Population Health
Examination Survey), conducted in 2003–2005,2 and in
2013–2014,3 included, respectively, 14 755 persons (7783
women) and 6163 persons (3406 women). In the years
2013–2014, the age-standardized prevalence of hyperten-
sion, awareness, treatment, and control were 42.7%,
59.3%, 46.1%, and 23%, respectively.3 Interestingly, in-
creased prevalence of hypertension, any anti-hypertensive
treatment and effective blood pressure (BP) control were
observed during the decade. In contrast, the awareness de-
creased non-significantly.2,3 The prevalence of hyperten-
sion in Poland is high and increased by some 12% in
10years. In another study, PolSenior, the random sample of
4950 participants aged 65–104years, participated in a
cross-sectional, nationally representative survey.4 About
80% of septuagenarians were hypertensive. Hypertension
prevalence decreased with age to 67% in females and 60%
in males over 90. In Poland, CVDs have been the leading
cause of mortality, however, with gradual decline since
1991. In 1991, CVDs caused 47.7% of all deaths (42.8% in
men and 53.3% in women).5 In 2014, 169 735 people died
due to CVDs (441.1/100 000). That accounted for 45.8% of
all deaths (40.9% in men and 51.1% in women).6 The age-
adjusted CVDmortality declined by 27% in males and 30% in
females in the years 1991–2013.6 May Measurement Month
(MMM) is a global initiative organized by the International
Society of Hypertension aimed at raising awareness of high
BP. The aim of the study in Polandwas to raise awareness of
BP and to detect untreated and uncontrolled hypertension.
Methods
An opportunistic cross-sectional survey of volunteers aged
18 was carried out in May 2017. BP measurement, the
definition of hypertension and statistical analysis followed
the approved MMM17 protocol. In Poland 5834 (98.9%,
White, Caucasian) individuals were screened. Each partici-
pant had their BP measured three times and received a
questionnaire about demographic, lifestyle, and environ-
mental factors. The study received the auspices of Polish
Societies of: Cardiology, Hypertension, Nephrology, Family
Physicians, and Study on Lipids and was approved by Local
Ethical Committee. A total of 443 study sites took part.
Funding came from non-public chains of family physicians’
network, non-public outpatients’ clinics, and pharmaceuti-
cal companies. Screenees were recruited by the public
health messages and endorsements, family physician offi-
ces, non-public outpatient clinics, and pharmacies. The
campaign started 8 May and lasted till 11 June. Three-
seated recordings were taken on the left arm (preferably)
with 1-min intervals between readings. Automated Omron
and Microlife healthcare electronic devices were used.
Hypertension was defined as systolic BP140mmHg or dia-
stolic BP 90mmHg, or both, or whether the participant
was receiving anti-hypertensive medication. Weight and
height were also measured. Data were collected via the
MMM App and analysed centrally by MMM project team.
Results
A total of 5834 subjects were screened, of whom 3351
were females and 2483 were males. Supplementary mate-
rial online, Table S1 presents basic characteristics of the
studied population. Most of the measurements were taken
during working days, but also representative datawere col-
lected during weekends (see Supplementary material
online,Table S2), 5808 of the total 5834 participants
had three BP measurements. Both systolic and diastolic
values slightly decreased at each examination (see
Supplementary material online, Table S3).
In 2061(35.3%, n¼ 5833) hypertension was diagnosed
based on BP values, independently of the previous status
(hypertensives or not, treated or untreated). Of 1084
patients receiving anti-hypertensive medication 532
(49.1%) were uncontrolled. Our measurements revealed
hypertension in 976 (20.6%) subjects not on any anti-hyper-
tensive treatment.
Both systolic and diastolic BP increased with body
weight (BMI). Almost linear correlations are shown in
Supplementary material online, Figure S1. Systolic BP was
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significantly higher in patients treated with anti-hyperten-
sives, diabetics, with previous myocardial infarction or
stroke, in smokers and in alcohol consumers (see
Supplementary material online, Figure S2). Diastolic BP in
those groups was also higher but not always significantly.
Very interesting results were obtained when the days of
measurements were compared (see Supplementary mate-
rial online, Figure S3). Both systolic and diastolic BPs were
significantly lower on Sunday as compared to Monday.
Discussion
In 35.3% of the study population, BP values were consid-
ered hypertensive and of individuals receiving anti-hyper-
tensive medication, 532 (49.1%) had uncontrolled BP. In the
whole MMM17 study, BP was highest on Saturdays and
Sundays7 but in Poland they were lowest on Sunday—per-
haps reflecting the usual leisure enjoyed on Sunday. Our
results corroborate findings of the whole MMM17 study
when adjusted BP was higher in association with anti-hy-
pertensive medication, diabetes, cerebrovascular disease,
smoking, and alcohol consumption.7 MMM was the largest
study in Poland addressing treatment rates and hyperten-
sion control in adults. Our results suggest that opportunis-
tic screening can identify significant numbers with raised
BP for prompt diagnosis and treatment. In previously pub-
lished studies WOBASZ, NATPOL, and PolSenior,1–4 lower
numbers were examined. In addition, in WOBASZ sampling
was performed in three stages, stratified according to voi-
vodeships (Polish districts), type of community, and gen-
der.2,3 However, there are some limitations as BP
measurements were performed on only one visit.
Therefore, the WOBASZ results may either overestimate
the prevalence of hypertension and/or underestimate its
control. In addition, the presented BP categories in the
whole population include those treated, therefore
obtained rates of optimal, correct, and high optimal pres-
sure could be overestimated. In both WOBASZ studies, that
is 2003/20052 and 2013/2014,3 the average values of sys-
tolic and diastolic BP assessed in all subjects, in both with
and without diagnosed hypertension declined significantly
in Poland over the studied decade. The awareness, per-
centage of treated patients, and BP control have improved
over the decade, and in the WOBASZ II study in the whole
population aged 19–99 years they were 59.3%, 46.1%, and
23%, respectively.3 It was probably due to an increased
number of effectively treated patients, and an increased
number of patients with adequately controlled BP. We may
also speculate that it may be caused by healthier life-
style.8,9 On the other hand, only 27.1% of the patients aged
19–99 had optimal BP. In the most recent Polish study
LIPIDOGRAM2015, unpublished data yet, hypertension
prevalence was 40.1% in general primary care adult popula-
tion (35.3% in women, 48.3% in men). In the 2002 NATPOL
PLUS study, hypertension was diagnosed based on home
measurements of the respondents during three separate
visits. The prevalence of hypertension according to the
number of visits was 36.4%, 31.3%, and 29.4% for 1, 2, and 3
visits, respectively.1 Prevalence of hypertension increased
from 30% to 32% between 2002 and 20112 in NATPOL study,
whereas in WOBASZ studies it increased from 34.7% to
39.0% in the whole population. In our MMM17 study, hyper-
tension prevalence was similar (35.3%). However, aware-
ness of hypertension in the NATPOL study increased within
a decade from 66% to 72%,2 whereas in WOBASZ and
WOBASZ II studies it non-significantly decreased from
55.2% to 54.2%. The effectiveness of hypertension treat-
ment in NATPOL PLUS and NATPOL 2011 studies measured
the percentage of patients with SBP <140mmHg and DBP
<90mmHg among all patients with hypertension, which in-
creased over 10years from 12% to 26%.2 In MMM17 almost
half of the hypertensive patients have unsatisfactory BP
control. It strongly supports the rationale to raise not only
the awareness but also to ensure prompt and adequate
control of BP to prevent or at least delay long-term
complications.
Conclusions
MMM17 was one of the largest recent BP screening cam-
paigns in Poland. Elevated BP was found in about one-third
of the participants. Almost half of already treated individu-
als still had uncontrolled BP. Undetected and uncontrolled
hypertension is a problem that medical professionals in
outpatient settings should pay much more attention to. A
large-scale screening programme is justified since it can
identify substantial numbers of individuals with raised BP
and implement the appropriate treatment.
Supplementary material
Supplementary material is available at European Heart
Journal - Supplements online.
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